cardiovascular disease, diabetes and dyslipidemia
Conditions
Interventions
hydrogen tablet 2tab/day for 4 weeks >
placebo 2tab/day for 4 weeks
placebo 2tab/day for 4 weeks >
hydrogen tablet 2tab/day for 4 weeks
Sponsors
Tokorozawa Heart Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with cardiovascular diseases, diabetes and dyslipidemia 2) Out patients
Exclusion criteria
Exclusion criteria: 1) Poor-controlled hypertension (DBP>110) 2) Poor-controlled diabetes (HbA1c>8.0 %) 3) Secondary hypertension 4) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 5) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits. 6) End stage renal disease 7) Symptomatic (NYHA III or IV) congestive heart failure 8) Malignancies or other diseases with poor prognosis 9) Subjects whose doctor in charge do not agree to join the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Markers indicating oxidative stress (Oxidized albumin, isoprostane, 8-OHdG, MDA-LDL, FABP) 4 weeks after administration | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood lipids, glucose, HbA1c Markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), and early-staged kidney diseases (microalbuminuria) 4 weeks after administration | — |
Countries
Japan
Contacts
Public ContactMakoto Ayaori
Tokorozawa Heart Center Shintokoekimae Clinic
Outcome results
None listed